SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: james paterson who wrote (65)11/20/1998 7:00:00 PM
From: Heat Shock  Read Replies (1) of 236
 
To all: some odds and ends.

1. The StressGen/GZMO joint venture is mentioned briefly on the Genzyme site:
in a page about their gene therapy program:
genzyme.com

in a page about gene immunotherapy:
genzyme.com

2. The recent press release on 3rd quarter results contained the following remarks by StressGen chief Richard Glickman:

Glickman added, "We continue to expand our pipeline of new cancer therapeutics through our joint venture with Genzyme Molecular Oncology. We have seen some early, but compelling results with the use of gene fusions -- where we combine stress protein DNA with the DNA coding for specific antigens -- which has led the joint venture to focus its development efforts on the fusion approach. The targets for this research program are currently being evaluated."

As I understand previous information, the joint venture was going to use Genzyme's liposomal vector to deliver a stress protein gene into cancer cells. The target was ovarian cancer. It looks like the nature of the therapy is changing and the indication might be changing too. Hopefully, the changes are due to the wide variety of good possible courses of action.

StressGen's lead product, HspE7, has always struck me as by far the more solid clinical trial candidate anyway.

3. The release also mentions "HspE7, the Company's lead product which targets cervical dysplasia". The main endpoint in the clinical trial might be treatment of cervical dysplasia. That would be a lot easier get approval for than an endpoint involving cervical cancer.

4. Knowledgable biotech poster Richard Harmon has mentioned StressGen in the past and here is a new mention:
exchange2000.com:80/~wsapi/investor/reply-6502917

Heat.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News